explore -WSS

explore

author：knowledge 2025-10-01 22:58:20 - browse：853

This image provided by Novo Nordisk in January 2023, shows packaging for the company's Wegovy drug. — Novo Nordisk via AP

PHILADELPHIA — Novo Nordisk’s obesity drug Wegovy notably cut the risk of heart attacks in a landmark cardiovascular trial that affirms the treatment offers health benefits beyond weight loss.

The company in August had announced that in this trial, called Select, Wegovy reduced the overall rate of major heart problems — heart attacks, stroke, or cardiovascular-related death — by 20%. That finding, which was the primary outcome the trial set out to study, was stronger than many were expecting and led Novo’s stock to surge.

But details of the study, including risk reductions for each specific heart complication, were not released until Saturday, when they were presented here — before a standing-room only crowd — as the first major session of the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Male and female sex labels in research insufficient, scientists say

hotspot

WSS

Boston's new lab space is opening empty

RaDonda Vaught links Vanderbilt hospital issues to patient death

Why depression after traumatic brain injury is distinct

Changes to biosimilar regulatory framework must prioritize patients

Thermo Fisher plant for manufacturing gene therapies to expand

John Green on his newest strategy for fighting tuberculosis

Wikipedia

explore

knowledge

Drug repurposing or repositioning? The language matters

Emergency workers more likely to restrain Black patients: study

Trump demands the U.S. pay no more for drugs than other countries … again

Emergency workers more likely to restrain Black patients: study

Hepatitis C has a cure — but many Americans still lack access to it

Second xenotransplant done with gene

Dobbs anniversary: the lost opportunity of abortion as health care

Boston's new lab space is opening empty

BioMarin wins approval for gene therapy to treat hemophilia A

UCLA team creates talking throat patch for voice disorders

entertainment

Boston's new lab space is opening empty

Boston's new lab space is opening empty

FDA panel to weigh approval of NurOwn, controversial ALS drug

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Lasker Awards 2023: Winners in biomedical research

How many hemophilia patients actually want gene therapy?

hotspot

Wikipedia

hotspot

focus